close

Enter

Log in using OpenID

Imbruvica Market 2019 Latest Innovation, key Drivers, Restraints, Segment, Opportunities and Industry Analysis, Forecast Period 2025

embed
Global Imbruvica Market report includes market drivers, opportunity and key industry trends. Furthermore, the report provides an in-depth assessment of the market competition with company profiles of global manufacturers. Imbruvica molecule binds Br
Adroit Market Research
Global Imbruvica Market Size
by Application (Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia,
Waldenstroms Macroglobulinemia, Relapsed/Refractory Marginal Zone
Lymphoma and Chronic Graft-Versus-Host-Disease), Region and
Forecast 2019 to 2025
Single Use License: US$ 4950
+1 (214) 884-6068
[email protected]
www.adroitmarketresearch.com
Request Sample
Adroit Market Research
Imbruvica Market Size and Forecast 2018-2025
• Global Imbruvica market report includes market drivers, opportunity and key industry trends. Furthermore, the report provides an in-depth
assessment of the market competition with company profiles of global manufacturers.
• The market research report on Imbruvica market evaluates the market demand, adoption rate and trending scenario for the period 2015 to
2025. The report highlights the historic trends from 2015 to 2017 and market forecast from 2019 to 2025.
• The global Imbruvica market is projected to witness significant growth, rising with a CAGR of 26.5% over the forecast period. The
market is projected to reach USD 31,773.40 million by 2025.
• Imbruvica is used for the treatment of Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, Waldenström's Macroglobulinemia,
Relapsed/Refractory Marginal Zone Lymphoma and Chronic Graft-Versus-Host-Disease. In the U.S. Imbruvica is popularly used for
all the above mentioned indications, however in rest of the countries worldwide Imbruvica is majorly used for the treatment of
Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia and Waldenström’s Macroglobulinemia. Thus, Chronic Lymphocytic
Leukemia is expected to grow at a highest CAGR of 27.3% by 2025.
• Imbruvica molecule binds Bruton’s tyrosine kinase (BTK) receptor in B-cells. It is used to treat various types of Leukemia and
Lymphoma arising from B-cells.
Browse the complete
reports/imbruvica-market
+1 (214) 884-6068
report
[email protected]
on
@
https://www.adroitmarketresearch.com/industry-
www.adroitmarketresearch.com
Adroit Market Research
Imbruvica Market Size and Forecast 2018-2025
• Global Imbruvica market has been segmented based on application, into Mantle Cell Lymphoma, Chronic
Lymphocytic Leukemia, Waldenström's Macroglobulinemia, Relapsed/Refractory Marginal Zone Lymphoma and
Chronic Graft-Versus-Host-Disease. Chronic Lymphocytic Leukemia accounted for the largest segment in 2018,
followed by Mantle Cell Lymphoma. Additionally, CLL is also anticipated to outpace other application during the
forecast period, growing with a CAGR of 27.3%.
• Imbruvica market is spread across the U.S., Europe, China, Japan, India, Southeast Asia and Latin America. U.S.
dominated the global Imbruvica market in 2018, with 76.1% market share, however, Europe is expected to show
the highest CAGR of 27.6% over the forecast period.
• Imbruvica comes under the category of orphan drugs, which affect only a small number of population, i.e.,
< 5/ 2,000 people in Europe, most often at birth. Around, 4000 to 5000 orphan diseases worldwide, have
no treatment options. In Europe, 25-30 million people are reported to be affected by these diseases.
• In Europe, pancreatic cancer has the least survival rate among all cancers. Over 95,000 people in Europe die of
pancreatic cancer each year; the median survival time at the point of diagnosis with just 4.6 months, patients lose
98% of their healthy life expectancy.
+1 (214) 884-6068
[email protected]
www.adroitmarketresearch.com
Adroit Market Research
Key segments of the Imbruvica Market
• Application Overview, 2015-2025 (USD Million)
•
•
•
•
•
Mantle Cell Lymphoma
Chronic Lymphocytic Leukaemia
Waldenström's Macroglobulinemia
Relapsed/Refractory Marginal Zone Lymphoma
Chronic Graft-Versus-Host-Disease
• Regional Overview, 2015-2025 (USD Million)
•
•
•
•
•
•
•
U.S
Europe
India
Japan
China
Southeast Asia
Central & South America
Purchase a single user copy of the Imbruvica Market report @
https://www.adroitmarketresearch.com/researchreport/purchase/839
+1 (214) 884-6068
[email protected]
www.adroitmarketresearch.com
Adroit Market Research
About Us
Contact Us
Adroit Market Research is an India-based business analytics and consulting company. Our
target audience is a wide range of corporations, manufacturing companies, product/technology
development institutions and industry associations that require understanding of a market’s
size, key trends, participants and future outlook of an industry. We intend to become our
clients’ knowledge partner and provide them with valuable market insights to help create
opportunities that increase their revenues. We follow a code– Explore, Learn and Transform. At
our core, we are curious people who love to identify and understand industry patterns, create
an insightful study around our findings and churn out money-making roadmaps. Our analysts
have tracked high growth markets in chemicals & materials, healthcare & pharmaceuticals,
semiconductor & electronics, energy & power, food & retail, consumer goods, technology, and
machinery & equipment sectors across the world to identify new opportunities, potential
customers, prepare go-to-market (GTM) strategies, identify segments for revenue growth for
companies, and many more.
US Headquarters
3131 McKinney Ave Ste 600 Dallas,
TX 75204 ,U.S.A
+1 (214) 884-6068
[email protected]
Phone: +1 (214) 884-6068
Email: [email protected]
www.adroitmarketresearch.com
1/--pages
Report inappropriate content